Methotrexate therapy in systemic lupus erythematosus

Abstract

There are 12 non-controlled and only two controlled studies using methotrexate (MTX) in a total of 207 SLE patients in the literature. The majority of these studies evaluated mainly cutaneous and/or articular involvement and attained good results. Two studies evaluated a small number ofpatients with lupus nephritis, achieving discordant results. Two other studies in pediatric onset systemic lupus erythematosus (SLE) also presented conflicting results, it being relevant that the one with poor response hadthe majority of patients with nephritis. One of the controlled trials was retrospective and concluded that MTX was effective in the treatment of antimalarial-resistant lupus arthritis and that toxicity leading to discontinuation of MTX was infrequent. The other controlled study was a double-blind, randomized, placebo-controlled clinical trial that evaluated SLE patients with mild activity. The authors concluded that MTX was effective in controlling cutaneous and articular activity and permitted prednisone dose reduction. The side effects were frequent but only 10% of patients needed to discontinue the medication.

The accumulative evidence suggests that MTX in a low weekly dose may be effective in SLE patients with articular and/or cutaneous involvement with no response to antimalarials and low-dose prednisone and in patients in whom we can not reduce prednisone dose due to articular or cutaneous activity. Caution is required concerning the side effects.

Keywords

methotrexate systemic lupus erythematosus therapy

Get full access to this article

View all access options for this article.

References

O'Dell JR . Methotrexate use in rheumatoid arthritis . Rheum Dis Clin N Am 1997; 23: 779-796 .

Miescher PA , Riethmuller D . Diagnosis and treatment of systemic lupus erythematosus . Sem Hematol 1965; 2: 1-28 .

Dubois EL . Management of discoid and systemic lupus erythematosus: a review of the current status of discoid and systemic lupus erythematosus and their variants. In: Systemic Lupus Erythematosus. University Southern California Press: Los Angeles, CA , 1974, pp 537-612.

Rothemberg RJ , Graziano FM , Gransone JT , Goldenberg JW , Bjarnason DF , Finesilver RG . The use of methotrexate in steroid resistant systemic lupus erythematosus . Arthrit Rheum 1988, 31: 612-615 .

Wilke WS , Krall RJ , Scheetz TB et al. Methotrexate for systemic lupus erythematosus: a retrospective analysis of 17 unselected cases . Clin Exp Rheumatol 1991; 9: 581-587 .

Wilson K , Abeles M . A 2 y, open ended trial of methotrexate in systemic lupus erythematosus . J Rheumatol 1994; 21: 1674-1677 .

Arfi S , Numeric P , Grollier L , Panelatti G , Jean-Baptiste G . Traitement du lupus erythemateux systemique corticodependant par le methotrexate á faibles doses . Rev Med Interne 1995; 16: 885-890 .

Gansauge S , Breitbart A , Rinald N , Schwarz Ewill M . Methotrexate in patients with moderate systemic lupus erythematosus (exclusion of renal and central nervous system disease) . Ann Rheum Dis 1997; 56: 382-385 .

Wise CM , Vuyyuru S , Roberts WN . Methotrexate in nonrenal lupus and undifferentiated connective tissue disease — a review of 36 patients . J Rheumatol 1966; 23: 1005-1010 .

10.

Galarza D , Esquivel J , Villarreal M , La Garza N , Garza M . Methotrexate in lupus nephritis: an uncontrolled study, preliminary results . Arthrit Rheum 1992; 34(Suppl): 187-187 (abstract).

11.

Abud-Mendoza C , Sturbaum AK , Vasquez-Compean R , Gonzalez-Amaro R . Methotrexate therapy in childhood systemic lupus erythematosus . J Rheumatol 1992; 20: 731-733 .

12.

Ravelli A , Ballardini G , Viola S , Villa I , Ruperto N , Martini A . Methotrexate therapy in refractory pediatric onset systemic lupus erythematosus . J Rheumatol 1988; 25: 572-575 .

13.

Kipen Y , Littlejohn GO , Morand EF . Methotrexate use in systemic lupus erythematosus . Lupus 1997; 6: 385-389 .

14.

Rahman P , Humphrey-Murto S , Gladman DD , Urowitz MB . Efficacy and tolerability of methotrexate in antimalarial resistant lupus arthritis . J Rheumatol 1998; 25: 243-246 .

15.

Carneiro JRM , Sato EI . Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus . J Rheumatol 1999; 26: 1275-1279 .

16.

Petri M , Rounbenoff R , Dallal GE et al. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus . Lancet 1996; 348: 1120-1124 .